SCHEMBL2369291

SCHEMBL2369291

Cc1cccc(CNc2nc(C(CO)CO)nc3scc(-c4ccc5c(c4)OCO5)c23)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 9/20 0.41
CYP2D6 P10635 9/20 0.41
MAPK1 P28482 8/20 0.41
CYP3A4 P08684 8/20 0.41
CLK4 Q9HAZ1 6/20 0.41
LMNA P02545 6/20 0.41
TDP1 Q9NUW8 3/20 0.40
CLK1 P49759 1/20 0.40
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
DYRK1A Q13627 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
CYP2C19 P33261 8/20 0.40
TSHR P16473 7/20 0.40
HSD17B10 Q99714 6/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368286 0.88 CLK4 (0.49) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL3383460 0.87 PRKCZ (0.43) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL2368333 0.86 TSHR (0.43) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL2369002 0.85 ESR1 (0.48) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL2368813 0.85 CYP1A2 (0.38) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL2368958 0.85 CYP1A2 (0.41) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL2368753 0.85 ESR1 (0.48) MAPK1LMNAPIP4K2CKDM4EMAPT
SCHEMBL2368960 0.84 ESR1 (0.39) MAPK1LMNAPIP4K2CMEN1KMT2A
SCHEMBL2368351 0.84 CCNE2 (0.41) CYP1A2CYP2D6MAPK1CYP3A4CLK4
SCHEMBL6357825 0.82 CYP1A2 (0.44) CYP1A2CYP2D6MAPK1CYP3A4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 CYP1A2 226/4885CYP2D6 225/4885MAPK1 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.